Eluxadoline Bile Acid Malabsorption (BAM) Study

Irritable Bowel Syndrome With Diarrhea Clinical Trial

Official title:

3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03441581
• Other study ID #: 3030-401-002
• Status: Completed
• Phase: Phase 4
• Start date: February 23, 2018
• Est. completion date: April 28, 2020

Study information

• Verified date: April 2021
• Source: Allergan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: April 28, 2020
• Est. primary completion date: April 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adult men or women aged 18 to 75 years inclusive with a diagnosis of IBS-D per Rome IV criteria.

• Participants with evidence of BAM must have a fasting serum 7a-hydroxy-4-cholesten-3-one (7aC4) level = 52.5 ng/mL or total fecal bile acid (BA) > 2337 micromoles/48 hours (positive result) at screening or within 1 calendar year prior to screening.

• Participants without BAM must have a fasting serum 7aC4 level = 47.1 ng/mL or total fecal BA < 2200 micromoles/48 hours (negative result) at screening or within 1 calendar year prior to screening.

• Has an average daily Bristol Stool Form Scale (BSFS) score = 5.0 or = 25% of diary entry days with a BSFS score of 6 or 7 during the 14 days prior to Day 1.

• Women of childbearing potential must use hormonal or double barrier contraception or maintain a monogamous relationship with a vasectomized male partner from the date of informed consent until 24 hours after final dose of study drug.

• Completed the electronic diary (eDiary) on = 10 of the 14 days prior to Day 1.

• Has not used loperamide rescue medication on > 3 of the 14 days prior to Day 1.

Exclusion Criteria:

• Has a diagnosis of IBS with a subtype of irritable bowel syndrome with constipation (IBS-C), mixed IBS, or unsubtyped IBS per Rome IV criteria.

• Does not have a gallbladder.

• Has known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction. (Participants with a history of gallstones may be enrolled).

• Has a history of alcoholism, alcohol abuse or alcohol addiction, or drinks more than 3 alcoholic beverages per day.

• Has a history of pancreatitis; structural diseases of the pancreas, including known or suspected pancreatic duct obstruction.

• Has a history of mild, moderate, or severe hepatic impairment according to Child-Pugh classification. History or current diagnosis of inflammatory or immune-mediated gastrointestinal (GI) disorders.

• Has Celiac disease or a positive serological test for celiac disease.

• Has known lactose or fructose intolerance associated with diarrhea, abdominal pain or discomfort, that could confound assessments in the study.

• Women who are currently pregnant or nursing, or plan to become pregnant or nurse during the study.

• Has known allergies or hypersensitivity to opioids.

Related Conditions & MeSH terms

• Diarrhea
• Irritable Bowel Syndrome
• Irritable Bowel Syndrome With Diarrhea
• Malabsorption Syndromes
• Syndrome

Intervention

Drug:
• Eluxadoline
Eluxadoline 100 mg oral tablets BID with food.

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period	Stool consistency was assessed using the BSFS where: 1=Separate hard lumps like nuts to 7=Watery. The score was recorded by the participant in an electronic diary (e-diary). The score for each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.	Baseline (Day 1) to Week 4
Primary	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)	An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.	Baseline (Day 1) to Week 4
Primary	Number of Participants Who Experienced Potentially Clinically Significant Change in Laboratory Tests	Laboratory tests included tests of Clinical Chemistry, Hematology, and Urinalysis. The investigator determined if the result was potentially clinically significant.	Baseline (Day 1) to Week 4
Primary	Number of Participants Who Experienced Potentially Clinically Significant Change in Vital Signs	Vital signs assessments included: pulse, respiratory rate, and blood pressure (systolic and diastolic). The investigator determined if the result was potentially clinically significant.	Baseline (Day 1) to Week 4
Primary	Number of Participants Who Experienced Clinically Significant Change From Baseline in General Physical Condition as Measured Through General Physical Exam	General Physical Examination consisted of a full review of body systems excluding pelvic and rectal exams. The investigator determined if the result was clinically significant.	Baseline (Day 1) to Week 4
Secondary	Change From Baseline in the 4-week Average of Daily Bowel Movement Frequency During the Treatment Period	Bowel movements were recorded by the participant in an electronic diary (e-diary). The number of bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.	Baseline (Day 1) to Week 4
Secondary	Change From Baseline in the 4-week Average of Daily Worst Abdominal Pain Scores During the Treatment Period	The participant recorded their worst abdominal pain score in the past 24 hours each day in an e-diary where: 0=no pain to 10=worst imaginable pain. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.	Baseline (Day 1) to Week 4
Secondary	Change From Baseline in the 4-week Average of Daily Bloating Scores During the Treatment Period	The participant recorded their bloating score in the past 24 hours each day in an e-diary where: 0=no bloating to 10=worst imaginable bloating. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.	Baseline (Day 1) to Week 4
Secondary	Change From Baseline in the 4-week Average Number of Daily Urgent Bowel Movements During the Treatment Period	The participant recorded the number of urgent bowel movements in the past 24 hours each day in an e-diary. The number of urgent bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.	Baseline (Day 1) to Week 4
Secondary	Percentage of Participants With Any Fecal Incontinence During the Treatment Period	The participant recorded the number of fecal incontinences in the past 24 hours each day in an e-diary. Fecal incontinence is the inability to control the passage of gas or stools. The number of fecal incontinences per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.	Baseline (Day 1) to Week 4
Secondary	Change From Baseline in Irritable Bowel Syndrome Quality of Life (IBS-QOL) Total Score at the End of the Treatment Period	IBS-QOL is composed of 34 items about how the symptoms of IBS are impacting the participant's life scored on a 1 to 5 scale, where lower item scores indicate greater quality of life. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0 to 100-point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates improved quality of life.	Baseline (Day1) to End of Treatment (Up to Week 4)
Secondary	Change From Baseline in Fasting Serum 7a-hydroxy-4-cholesten-3-one (7aC4) Levels at the End of the Treatment Period	Participants fasted for at least 8 hours prior to the test. Fasting serum 7aC4 level was measured at Baseline and End of Treatment to determine whether any changes occurred following treatment with eluxadoline. The negative change from Baseline indicates improvement.	Baseline (Day 1) to End of Treatment (Up to Week 4)
Secondary	Cmax: Maximum Concentration for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2
Secondary	Cmin: Minimum Concentration for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2
Secondary	AUC: Area Under the Concentration-time Curve During the Dosing Interval for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2
Secondary	Tmax: Time to Cmax for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2
Secondary	t1/2: Half-Life for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2
Secondary	CL/F: Apparent Total Clearance of the Drug From Plasma After Oral Administration for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2
Secondary	Vc/F: Apparent Volume of Distribution for Eluxadoline		Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2